Multicenter Study of \textit{Cronobacter sakazakii} Infections in Humans, Europe, 2017

Sarah Lepuschitz, Werner Ruppitsch, Shiva Pekard-Amenitsch, Stephen J. Forsythe, Martin Cormican, Robert L. Mach, Denis Piérard, Franz Allerberger, the EUCRONI Study Group

\textit{Cronobacter sakazakii} has been documented as a cause of life-threatening infections, predominantly in neonates. We conducted a multicenter study to assess the occurrence of \textit{C. sakazakii} across Europe and the extent of clonality for outbreak detection. National coordinators representing 24 countries in Europe were requested to submit all human \textit{C. sakazakii} isolates collected during 2017 to a study center in Austria. Testing at the center included species identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, subtyping by whole-genome sequencing (WGS), and determination of antimicrobial resistance. Eleven countries sent 77 isolates, including 36 isolates from 2017 and 41 historical isolates. Fifty-nine isolates were confirmed as \textit{C. sakazakii} by WGS, highlighting the challenge of correctly identifying \textit{Cronobacter} spp. WGS-based typing revealed high strain diversity, indicating absence of multinational outbreaks in 2017, but identified 4 previously unpublished historical outbreaks. WGS is the recommended method for accurate identification, typing, and detection of this pathogen.

\textit{Cronobacter sakazakii} is a motile, gram-negative, rod-shaped opportunistic pathogen of the family \textit{Enterobacteriaceae} \cite{1}. In 2007, organisms previously classified as \textit{Enterobacter sakazakii} were reassigned to the new genus \textit{Cronobacter}, which now consists of 7 species: \textit{C. sakazakii}, \textit{C. condimenti}, \textit{C. dublinensis}, \textit{C. malonicus}, \textit{C. muytjensii}, \textit{C. turicensis}, and \textit{C. universalis} \cite{2,3}. \textit{C. sakazakii} has been isolated from various environments (e.g., domestic environments and manufacturing plants), clinical sources (e.g., cerebrospinal fluid, blood, and sputum), food (e.g., cheese, meat, and vegetables), and animals (e.g., rats and flies) \cite{4,5}.

Most reported cases of illness caused by \textit{C. sakazakii} are in infants <2 months old \cite{6,7}. Premature infants and infants with underlying medical conditions are at the greatest risk for illness. Numerous outbreaks caused by \textit{C. sakazakii} have been traced to contaminated powdered infant formula \cite{8}. Powdered infant formula is not a sterile product, and the ability of \textit{C. sakazakii} to tolerate dry conditions enables it to survive for long periods in the final powdered product \cite{9}.

The screening of food (particularly powdered formula) was proposed to reduce the risk to neonatal and infant health \cite{10,11}. The most common syndromes of foodborne infection in infants include necrotizing enterocolitis (NEC), bacteremia, and meningitis \cite{12,13}. Examples of outbreaks of illness in hospital neonatal units caused by \textit{C. sakazakii} associated with powdered infant formula have been compiled by Iversen and Forsythe \cite{6} and by Lund \cite{8}.

A few cases of illness (usually nongastrointestinal) in adults caused by \textit{C. sakazakii} have been reported. In most of these cases the adults had underlying diseases, and no evidence of foodborne transmission was reported \cite{14,15}.

We performed a multicenter study of \textit{C. sakazakii} infections in humans (EUCRONI) to determine the occurrence of \textit{C. sakazakii} in clinical microbiology laboratories across Europe. We also assessed the extent of clonality for human \textit{C. sakazakii} isolates.

Material and Methods

Study Design

EUCRONI consisted of national coordinators (EUCRONI study group members) from 24 countries in Europe. Coordinators had to actively approach all medical microbiology laboratories to collect human \textit{C. sakazakii} isolates (1 per patient) in their respective countries during 2017. Human historical isolates (with isolation dates before 2017) were also accepted. The 24 participating countries were arbitrarily chosen to reflect a wide geographic and

Author affiliations: Austrian Agency for Health and Food Safety, Vienna, Austria (S. Lepuschitz, W. Ruppitsch, S. Pekard-Amenitsch, F. Allerberger); Vienna University of Technology, Vienna (S. Lepuschitz, R.L. Mach); foodmicrobe.com, Keyworth, United Kingdom (S.J. Forsythe); National University of Ireland, Galway, Ireland (M. Cormican); Universitair Ziekenhuis Brussel, Brussels, Belgium (D. Piérard)

DOI: https://doi.org/10.3201/eid2503.181652

1Members of the EUCRONI study group are listed at the end of this article.
socioeconomic range (Figure 1). Isolates were transferred to the study center (Austrian Agency for Health and Food Safety, Vienna, Austria) for whole-genome sequencing (WGS), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) analysis, and antimicrobial drug susceptibility testing. We submitted data capture forms to national coordinators to collect the following demographic data: patient age and sex, patient status (colonized or infected), specimen source, type of healthcare facility requesting the microbiologic culture, and date of specimen collection.

**Species Identification and DNA Extraction**

We cultured isolates on Columbia blood agar plates (bio-Mérieux, http://www.biomerieux.com/) overnight at 37°C. We performed species identification by using MALDI-TOF Biotyper (Bruker, https://www.bruker.com) and MBT Compass IVD 4.1.60 (Bruker) according to the manufacturer’s instructions. We conducted isolation, quantification, and WGS of genomic DNA according to methods described by Lepuschitz et al. (16). We used Sequencing Coverage Calculator (http://www.illumina.com) for calculation of a desired mean coverage of ≥80-fold.

**WGS Data Analysis**

We de novo assembled raw reads by using SPAdes version 3.9.0 (17) and processed them in SeqSphere+ (Ridom GmbH, https://www.ridom.de) for bacterial typing. We deposited the genome sequences in the PubMLST Cronobacter database (https://pubmlst.org/Cronobacter) under accession nos. 2403 and 2495–2552. To determine the core genome multilocus sequence type (cgMLST) gene set, we performed a genome-wide gene-by-gene comparison by using the MLST+ target definer function of SeqSphere+

---

**Figure 1.** Countries participating in a multicenter study of Cronobacter sakazakii infections in humans, Europe, 2017. Dark green indicates the 8 countries that sent C. sakazakii isolates to the study center in Austria; light green indicates the 3 countries where historical outbreaks were detected; and red indicates the 13 countries that participated but did not provide isolates. AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FR, France; GR, Greece; HR, Croatia; IE, Ireland; IT, Italy; LV, Latvia; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SI, Slovenia; UK, United Kingdom.
as described previously (18) with default parameters and the complete genome of C. sakazakii strain ATCC BAA-894 (19) as reference genome, all complete C. sakazakii genomes available at GenBank, 8 isolates retrieved from whole-genome shotgun sequencing projects, and 4 C. sakazakii isolates sequenced at the Austria study center as query genomes. We extracted sequences of the 7 genes comprising the allelic profile of the classical MLST scheme and queried them against the C. sakazakii MLST database (1), assigning classical sequence types (STs) in silico. We obtained additional species confirmation by using JSpeciesWS (20) and ribosomal MLST (21). We included 23 C. sakazakii historical isolates from 4 different outbreaks (F. Allerberger, 2016; F. Barbut, 2010–2016; G. Feierl, 2009; D. Piérard, 1997–1998, all unpub. data; Appendix Table 1, https://wwwnc.cdc.gov/EID/article/25/3/18-1652-App1.xlsx) and 3 reference strains, ATCC BAA-894 (19), ATCC29544 (PRJNA224116), and NCTC 8155 (PRJNA224116), to determine the level of microevolution.

**Antimicrobial Resistance Testing**

We performed in vitro susceptibility testing with the VITEK 2 Compact System (bioMérieux) and interpreted the VITEK 2 AST196 card according to European Committee on Antimicrobial Susceptibility Testing criteria for Enterobacteriaceae (Clinical Breakpoint Tables version 8.0, http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents). For detection of antibiotic resistance genes, we used the Comprehensive Antibiotic Resistance Database (22) with default settings “perfect” and “strict” for sequence analysis. We tested isolates in SeqSphere+ for Cronobacter-specific variant ampC (e.g., CSA-1, CSA-2, CMA-1, and CMA-2) (23).

**Results**

**Strain Collection and Primary Species Identification**

During the study period, 11 of 24 national coordinators (Figure 1) provided 77 presumptive C. sakazakii isolates previously identified by conventional biochemical testing, local MALDI-TOF MS analysis (Bruker Biotype and VITEK MS), locally performed Cronobacter genus- and species-specific PCRs, or 16S rRNA gene sequence analysis. These 77 isolates consisted of 36 human isolates from 2017 and 41 historical human isolates obtained during 1964–2016. The participating laboratories, using local conventional phenotypical methods or local MALDI-TOF MS analysis, incorrectly identified 18 (23.4%) of 77 human isolates as C. sakazakii.

MALDI-TOF MS analysis in the study center identified 69 of 77 isolates as C. sakazakii; 1 isolate from 2017 yielded low-confidence identification (log[score] value 1.70–1.99). We assigned 7 clinical isolates from 2017 and 1 historical clinical isolate from 2005 to other species (Table 1). The WGS-based species identification using JSpeciesWS and rMLST confirmed MALDI-TOF MS identification results in all but 10 of the 69 isolates. WGS indicated that 5 isolates were C. malonaticus, 2 were C. turicensis, 1 was C. dublinensis, 1 was C. universalis, and 1 was Siccibacter turicensis (Table 1; Appendix Table 1).

**Human C. sakazakii Isolates Collected in 2017**

In total, 21 C. sakazakii isolates from 21 patients were collected in 2017 in 9 participating countries in Europe. Case-fatality ratio (within 30 days after specimen collection) was 2 of 21 case-patients (Table 2).

**Molecular Typing of Bacterial Isolates**

The defined cgMLST gene set consisted of a total of 2,831 core and 1,017 accessory targets. Of 77 sequenced isolates, 59 isolates were confirmed as C. sakazakii; these isolates had on average 99.4% of good core genome targets (97.7% to 99.9%) (18) and revealed in total 17 different sequence types (STs) (Table 3).

Core genome comparison of 59 C. sakazakii isolates and the 3 reference strains revealed an average allelic difference of 2,402 and a maximum allelic difference of 2,724 (Figure 2). Isolates clustered in the minimum-
spawning tree to their respective MLST. Eight isolates belonging to ST1 included 2 stool isolates from neonates
with a common epidemiologic link in Austria in 2009; these 8 isolates showed 1 allelic difference and were
most closely related (203 alleles difference) to a historical strain from Denmark isolated in 2003. That outbreak
affected 2 neonates with necrotizing enterocolitis (both male, age 10 days and 12 days) hospitalized in the same
neonatal intensive care unit.

Twelve isolates belonged to ST4, of which 3 were con-
formed isolates from infants. Two infant isolates belonged
to an outbreak cluster with a common epidemiologic link
detected in Austria in 2016; these isolates shared the same
cgMLST profile and showed a maximum of 47 allelic dif-
fferences to the historical reference strain NCTC 8155 (from
milk, United Kingdom, 1950). This outbreak again affected
2 neonates (neonate A: female, age 22 days, positive blood
culture, fatal outcome; neonate B: male, age 16 days, posi-
tive respiratory tract specimen) hospitalized in the neonatal
intensive care unit of another hospital in Austria. The
third infant isolate was a 2017 ST4 isolate from a case in
Austria with a fatal outcome and was most closely related
(302 allelic differences) to a historical strain from Denmark
isolated in 2003.

Six clinical isolates assigned to ST8 consisted of 2
historical human isolates from Canada (date of isolation
unknown). These 6 isolates shared the identical core ge-
nome profile and had 1 allelic difference to reference strain
ATCC29544 (from an infant, United States, 1970).

Nine human isolates assigned to ST21 comprised his-
torical outbreak cluster from France collected during 2010–
2016. The outbreak included 3 female patients (mean age
62 years) and 5 male patients (mean age 68 years); initial
specimens were abscess material from the digestive tract
(n = 1), ascites fluid (n = 1), respiratory tract specimens (n
= 2), and rectal swab specimens (n = 4). Eight of these 9
isolates showed the same core genome genes, and 1 yielded
1 allelic difference.

All 10 isolates assigned to ST155 belonged to a histori-
ical outbreak among infants in Belgium during 1997–1998;
the isolates originated from blood cultures (n = 2), stool
specimens (n = 2), rectal swab specimens (n = 4), and re-
spiratory tract specimens (n = 2). The first positive sample
was collected in November 1997; the remaining 9 speci-
mens were obtained during August–September 1998. Eight

### Table 2. Characteristics of patients enrolled and *Cronobacter sakazakii* isolates collected in a multicenter study of *C. sakazakii* infections in humans, Europe, 2017*

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Country of origin</th>
<th>Patient age, y/sex</th>
<th>Specimen source</th>
<th>Death within 30 d</th>
<th>MLST</th>
</tr>
</thead>
<tbody>
<tr>
<td>802520</td>
<td>Austria</td>
<td>73/F</td>
<td>Stool</td>
<td>No</td>
<td>630</td>
</tr>
<tr>
<td>7750-17</td>
<td>Austria</td>
<td>&lt;1/M</td>
<td>Blood</td>
<td>Yes</td>
<td>4</td>
</tr>
<tr>
<td>16862-17</td>
<td>Austria</td>
<td>77/F</td>
<td>Blood</td>
<td>No</td>
<td>37</td>
</tr>
<tr>
<td>808921</td>
<td>Austria</td>
<td>69/F</td>
<td>Stool</td>
<td>No</td>
<td>21</td>
</tr>
<tr>
<td>56487-17</td>
<td>Austria</td>
<td>78/M</td>
<td>Urine</td>
<td>No</td>
<td>17</td>
</tr>
<tr>
<td>101807-17</td>
<td>Austria</td>
<td>77/M</td>
<td>Blood</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>9929-17</td>
<td>Austria</td>
<td>5/M</td>
<td>Stool</td>
<td>No</td>
<td>17</td>
</tr>
<tr>
<td>EURCRO1016</td>
<td>Belgium</td>
<td>61/M</td>
<td>Urine</td>
<td>No</td>
<td>13</td>
</tr>
<tr>
<td>EURCRO1012</td>
<td>Belgium</td>
<td>78/M</td>
<td>Wound</td>
<td>No</td>
<td>31</td>
</tr>
<tr>
<td>1481-17</td>
<td>Czech Republic</td>
<td>80/F</td>
<td>Rectal swab</td>
<td>No</td>
<td>8</td>
</tr>
<tr>
<td>436-17</td>
<td>Czech Republic</td>
<td>31/M</td>
<td>Rectal swab</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>10965-17</td>
<td>Czech Republic</td>
<td>74/M</td>
<td>Rectal swab</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>D97986</td>
<td>Denmark</td>
<td>85/F</td>
<td>Sputum</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>17007483</td>
<td>Denmark</td>
<td>69/M</td>
<td>Urine</td>
<td>No</td>
<td>58</td>
</tr>
<tr>
<td>423410</td>
<td>Ireland</td>
<td>65/M</td>
<td>Blood</td>
<td>No</td>
<td>12</td>
</tr>
<tr>
<td>170215-0130</td>
<td>Norway</td>
<td>87/M</td>
<td>Blood</td>
<td>Yes</td>
<td>17</td>
</tr>
<tr>
<td>M732000</td>
<td>Portugal</td>
<td>60/M</td>
<td>Urine</td>
<td>No</td>
<td>40</td>
</tr>
<tr>
<td>80357408-17</td>
<td>Scotland</td>
<td>73/F</td>
<td>Stool</td>
<td>No</td>
<td>33</td>
</tr>
<tr>
<td>80363028-17</td>
<td>Scotland</td>
<td>71/M</td>
<td>Urine</td>
<td>No</td>
<td>4</td>
</tr>
<tr>
<td>07_2005</td>
<td>Slovenia</td>
<td>54/M</td>
<td>Tracheal aspirate</td>
<td>No</td>
<td>184</td>
</tr>
<tr>
<td>2017C1</td>
<td>Switzerland</td>
<td>55/F</td>
<td>Cervix uteri</td>
<td>No</td>
<td>40</td>
</tr>
</tbody>
</table>

*MLST, multilocus sequence type.

### Table 3. In silico evaluation of MLSTs for *Cronobacter sakazakii* strains in a multicenter study of *C. sakazakii* infections in humans, Europe, 2017*

<table>
<thead>
<tr>
<th>MLST</th>
<th>Total no. isolates</th>
<th>Human isolates detected in 2017</th>
<th>Historical human isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>13</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>148</td>
<td>1</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>155</td>
<td>10</td>
<td>–</td>
<td>10</td>
</tr>
<tr>
<td>17</td>
<td>3</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td>184</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>21</td>
<td>10</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>31</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>33</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>37</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>40</td>
<td>2</td>
<td>2</td>
<td>–</td>
</tr>
<tr>
<td>50</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>58</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>630</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

*MLST, multilocus sequence type; –, no isolates detected.
of the 10 isolates shared the same cgMLST profile, and 2 had 1 allelic difference.

In total, 27 of 38 historical isolates were most closely related (≤1 allelic difference) to other historical isolates; 11 were singletons. All 21 isolates collected in 2017 were singletons, and no close relatedness was evident (>100 allelic differences) between historical isolates and isolates from 2017.

**In Vitro and In Silico Antimicrobial Resistance Analysis**

In vitro susceptibility testing of 21 human *C. sakazakii* isolates from 2017 revealed 20 *C. sakazakii* isolates that were susceptible to all 14 tested antibiotics (Appendix Table 2). One isolate was resistant to ampicillin, cefotaxime, gentamicin (intermediate), moxifloxacin, and trimethoprim/sulfamethoxazole.

Of 21 *C. sakazakii* isolates, 12 isolates carried the efflux genes *emrB, msbA, patA*, regulatory systems modulating antibiotic efflux *CRP, marA, emrR, marR, H-NS*, antibiotic target protection gene *msrB*, and the determinant of fosfomycin resistance *glpT*. Seven isolates had in addition the antibiotic protection gene *vgaC*. One isolate had also the efflux gene *norB*, the antibiotic inactivation gene *fosX*, and the antibiotic target alteration gene *mpfR*. One isolate had the additional antibiotic inactivation genes *aac(6')-Ib-cr, aadA16, aadA2, ant(2')-Ia, arr-3, catB3, CTX-M-9, OXA-1*, the antibiotic target protection gene *qnrA1*, and the antibiotic target replacement gene *sul1*.

The presence of variant *ampC* was confirmed for all 21 isolates. Seventeen isolates harbored CSA-2, and 4 isolates harbored CSA-1 (Appendix Table 2).

**Discussion**

The aim of our 2017 *C. sakazakii* study was to assess the occurrence of this opportunistic pathogen in countries of Europe, characterize the isolates, and recognize possible multinational outbreaks. Our finding that only 59 of 77 presumptive *C. sakazakii* isolates had the species-identification
C. sakazakii confirmed at the central study center shows that correct identification of Cronobacter spp. is still a challenge for many routine laboratories.

The prevalence of reported C. sakazakii cases was low, with only 11 (45.8%) of 24 participating countries submitting C. sakazakii isolates. Clinical isolates from 2017 showed high genetic diversity, indicating that neither multinational nor national outbreaks occurred in 2017 in the 24 countries studied. However, characterization of the historical isolates obtained during this study confirmed occurrence of 4 previously unpublished historical outbreaks: 2 outbreaks from 2009 and 2016 in Austria, 1 from Belgium during 1997–1998, and 1 from France during 2010–2016. Hospitals affected by nosocomial C. sakazakii outbreaks might still be reluctant to publish possibly food-related outbreaks or nosocomial infections, especially in the case of affected infants and particularly in the case of related fatalities.

Strain typing using classical MLST identified a total of 17 STs among 59 sequenced C. sakazakii isolates. Our addition of a new ad hoc cgMLST scheme consisting of 2,831 core target genes provides more discriminative power for outbreak investigation and source tracking than the standard 7-loci MLST scheme.

The dominant STs found among our clinical C. sakazakii isolates from 2017 were ST4, ST17, ST1, and ST40, a distribution consistent with results from other studies (1). The medical literature often links C. sakazakii ST4 with powdered infant formula–associated outbreaks in infants (3). In our study, the sole strain (7750-17) affecting an infant (a 3-month-old baby boy who died) was ST4, isolated from a blood culture.

Antibiotic treatment is essential in the care of a patient with a confirmed Cronobacter infection. The traditional antibiotic regimen for Cronobacter spp. was ampicillin in combination with either gentamicin or chloramphenicol. In view of claimed resistance to ampicillin and most first- and second-generation cephalosporins, it has been suggested that carbapenems or third-generation cephalosporins be used with an aminoglycoside or trimethoprim/sulfamethoxazole (24). In our study, antimicrobial resistance testing showed susceptibility to all tested antibiotics for 20 of 21 human isolates from 2017. In comparison to other members of the family Enterobacteriaceae, Cronobacter strains seem to be more susceptible against so-called “key access antibiotics” of the World Health Organization’s Model List of Essential Medicines (25), such as ampicillin, aminoglycosides, chloramphenicol, and third-generation cephalosporins (the last is included in the List of Essential Medicines only for specific, limited indications) (26). For all isolates, we confirmed the presence of 1 of 4 tested ampC β-lactamase variants, which confer phenotypic resistance exclusively to first-generation cephalosporins (e.g., cephalothin) but not to ampicillin (23). A few studies have reported Cronobacter isolates conferring multidrug resistance (26), a phenomenon observed in our study only for 1 strain from Slovenia.

Correct species identification within the Cronobacter group was a major challenge for 7 of 11 participating laboratories. This identification problem is consistent with numerous misidentifications reported in the literature (27,28). The discrepancies in correct Cronobacter spp. identification on a genus and species level between the study center in Austria and the primary testing laboratories using MALDI-TOF MS is probably attributable to outdated databases used by primary testing laboratories. Nevertheless, our study showed that the overall MALDI-TOF MS performance for Cronobacter spp. identification on the species level is insufficient and misleading. The databases contained data for C. sakazakii only, and therefore all 7 species of the genus Cronobacter were identified as C. sakazakii. In addition, although a database comment indicated that Cronobacter could only be identified on the genus level, the MALDI-TOF MS result simulated the highest identification score for C. sakazakii. This shortfall should be corrected by an update of the MALDI-TOF MS databases to enable accurate Cronobacter identification at the species level. In comparison, WGS-based species identification represents a major improvement to conventional identification methods and MALDI-TOF MS (29). Therefore, we recommend the use of WGS-based identification tools and databases for identification of species within the Cronobacter group.

Adults were the main affected age group in our study. All but 2 of the isolates from 2017 originated from adults. This finding confirms the results from previous recent studies (14,30) and contradicts statements in numerous medical textbooks, postulating that infants are more often affected than adults (8,31–33).

Our study has some limitations. Lack of information (e.g., detailed epidemiologic and clinical patient data) and misidentification on genus and species levels, might have played a role in underestimating the real prevalence rate; 13 of the 24 participating countries did not find or did not submit C. sakazakii isolates.

In conclusion, this C. sakazakii study in Europe revealed a high strain diversity, which points to highly diverse infection sources and an absence of national or multinational outbreaks in 2017. Correct identification of C. sakazakii still poses a diagnostic challenge to many laboratories, and the use of such imperfect detection systems might explain the low prevalence of reported clinical C. sakazakii isolates found in this study. WGS data must be used for accurate species identification and high-resolution strain typing. We recommend the inclusion of C. sakazakii as a notifiable organism by public health authorities.
Members of the EUCRONI study group: F. Allerberger, Austrian Agency for Health and Food Safety, Vienna, Austria; A. Tambic Andrasevic, University Hospital for Infectious Diseases, Zagreb, Croatia; A. Balode, Pauls Stradiņš Clinical University Hospital, Riga, Latvia; F. Barbut, Hôpital Saint-Antoine, Paris, France; Irina Codita, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; M. Cormican, School of Medicine National University of Ireland Galway, Galway, Ireland; C. Ferguson, Victoria Hospital, Kirkcaldy, Scotland, United Kingdom; P. Heczko, Jagiellonian University Medical College, Kraków, Poland; O. Holy, Department of Preventive Medicine, Palacký University Olomouc, Czech Republic; T. Kantardjiev, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria; E.J. Kuijper, Leiden University Medical Center, Leiden, the Netherlands; T.M. Leegaard, Akershus University Hospital, Lorenskog, Norway; L.M.V. Peixe, University of Porto, Porto, Portugal; D. Piéard, Department of Laboratory Medicine, Universitätsklinikum Zürich, Switzerland; A. Tonioi, Università degli Studi dell’Insubria, Varese, Italy; T. Tošić, Clinical Center of Serbia, Belgrade, Serbia; S. Valdezate, Instituto de Salud Carlos III., Madrid, Spain; S. von Müller, Christophorus-Kliniken GmbH, Coesfeld, Germany; L. Zerva, Attikon-Hospital, Athens, Greece; and B. Zinieri-Panayide, General Hospital, Paphos, Cyprus.

Acknowledgments

We thank the following persons for their willingness to provide isolates and information to the national study coordinators: Charlotte Nielsen Agergaard, John Bingham, Nadine Botteldoorn, Carolyn Cameron, Urska Dermota, Harald Dirschmid, Astrid Dopita, Stefan Doppler, Gebhard Feierl, Manfred Fille, Sonja Fischelschweiger, J. Gigi, Maja Gošnjak, Nils Grude, Renée Haunold, Iren Hayland Löhr, Heidrun Kerschner, Uwe König, Helena Ramos, Tanja Vrabič, Slavica Lorencic Robnik, Tatjana Rupel, Helene Marchandin, Helga Masoud, Louise O’Connor, Renata Ocvirk, Christian Petternel, Catherine Potvielje, Christian Salgård Jensen, Gunnar Skov Simonsen, Bettina Titz, Herwig Tomantschger, Martin Tötsch, Svetlana Ugarcina Perovic, Birgit Willinger, and Markus Winkler.

This study was initiated and partially funded by ESCMID Food- and Water-borne Infections Study Group.

The authors have no conflict of interests to declare.

The institutional review board of the city of Vienna studied the protocol and decided on July 28, 2016, under EK 16-161-VK-NZ that the study did not require formal ethics review.

About the Author

Ms. Lepuschitz studied molecular biology with a focus on molecular medicine and is currently a PhD student focusing on infectious diseases at the Vienna University of Technology and the Austrian Agency for Health and Food Safety, Vienna, Austria. Her primary research interests include the characterization and epidemiology of clinical, foodborne, and environmental pathogens.

References


Address for correspondence: Sarah Lepuschitz, Austrian Agency for Health and Food Safety, Institute for Medical Microbiology and Hygiene, Waehringerstraße 25a, 1090 Vienna, Austria; email: sarah.lepuschitz@ages.at